Target intelligence / Profile preview

Nicotinic acetylcholine receptor alpha4beta2 subunit (α4β2 nAChR)

Target
α4β2 nAChR
Molecular classification
Ligand-gated ion channel, Receptor
01

Overview

The nicotinic acetylcholine receptor (nAChR) alpha4beta2 subtype (α4β2 nAChR) is a heteropentameric ligand-gated ion channel composed of alpha-4 (α4) and beta-2 (β2) subunits. It is the most abundant nicotinic receptor subtype in the mammalian brain and plays a central role in mediating the effects of nicotine, including its addictive properties. It is highly expressed throughout various brain regions implicated in cognition, reward processing, attention regulation, growth hormone secretion, learning/memory formation, and addiction pathways. The receptor exists in two main stoichiometric configurations: (α4)_3(β2)_2 (low nicotine sensitivity, high calcium permeability) and (α4)_2(β2)_3 (high nicotine sensitivity, low calcium permeability). Smoking cessation agents like varenicline act as partial agonists at α4β2 receptors.

02

Mechanism of action

Agonist or partial agonist binding leads to increased Na+ and K+ permeability across neuronal membranes, resulting in neuronal excitation. Antagonists block the receptor and prevent activation.

03

Biological functions

Fast synaptic transmissionModulation of attentionModulation of cognitionModulation of rewardNeuronal excitationGrowth hormone release
04

Disease associations

AddictionCognitive disordersObesityAttention deficit hyperactivity disorder (ADHD)
05

Safety considerations

Potential for seizuresCardiovascular effects
06

Interacting drugs

Acetylcholine

5 more in the full profile.

Beyond the preview

Go deeper on Nicotinic acetylcholine receptor alpha4beta2 subunit (α4β2 nAChR).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nicotinic acetylcholine receptor alpha4beta2 subunit (α4β2 nAChR).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call